Nanosphere, Inc., a company enhancing medicine through targeted molecular diagnostics, today announced that it will host an interactive webinar entitled: “Each Hour Counts: The Clinical and Economic Case for Rapid Sepsis Diagnostics.” The complimentary webinar will be held on Thursday, July 17, 2014 at 1:00 p.m. EDT.
To register for this event, please visit: xtalks.com/Clinical-Economic-Sepsis-Diagnostics.ashx.
In this webinar, Mike Saubolle, Ph.D., Medical Director of the Infectious Diseases Division of Laboratory Sciences of Arizona and Banner Health Hospitals; Bert Lopansri, M.D., Associate Professor of Medicine for the Division of Infectious Diseases at Intermountain Medical Center; and Melissa Miller, Ph.D., Director of the Clinical Molecular Microbiology Laboratory at the University of North Carolina School of Medicine, will review the importance of outcomes studies and explore data that have demonstrated the clinical and economic benefits of rapid, multiplex sepsis diagnostics.
Sepsis is the most expensive condition to treat in the U.S. and is one of the deadliest diseases. Delayed identification of the causative pathogen(s) and associated drug resistance can hinder effective treatment and worsen the patient outcome. Rapid identification of these pathogens provides vital information for clinicians to determine the optimal treatment for their patients. Effective implementation of rapid, multiplex diagnostics for sepsis is associated with improved patient outcomes, improved antimicrobial stewardship, improved infection control and reduced healthcare costs.
Attendees qualify to receive a P.A.C.E. continuing education credit for this webinar.
This will be the third webinar hosted by Nanosphere in its “Each Hour Counts” educational series. Archives of the previous two webinars are available for download at: xtalks.com/eachhourcounts.ashx and http://www.prweb.net/Redirect.aspx?id=aHR0cDovL3d3dy5ic2l3ZWJpbmFyLmNvbQ==.
About Nanosphere, Inc.
Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company’s versatile technology platform, the Verigene® System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere’s customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at nanosphere.us.